
Ministers are facing renewed scrutiny for delaying Palantir’s NHS exit until 2029, amid warnings that the health service could remain tied to the US tech giant long after its £330m contract ends.
The government confirmed this week that it would not exercise a break clause allowing it to end Palantir’s contract next year, instead giving the American firm another two years to run the health service’s Federated Data Platform (FDP).
The decision has prompted criticism from Labour MPs and campaigners, with Parliament set to debate Palantir’s removal from NHS systems.
Peter Griffiths, founder and chairman of Argyll Data Development, warned that replacing Palantir would do little to address Britain’s technological dependence unless ministers ensured the NHS could move its data and systems between suppliers.
“The NHS Palantir debate is really a question about the control of data,” he said. “The NHS is such a critical part of the UK’s national infrastructure that no single supplier should hold the keys to its data and systems.”
Stay in the know
Three daily briefings with the key market moves and top business and political stories.
SUBSCRIBE HEREGriffiths said the government must test whether data, applications and critical workloads could be transferred without disrupting patient care before awarding another contract.
“Sovereignty must be a priority for the government, and an exit clause only counts if the NHS can actually leave when it wants to,” he added.
Pressure mounts on US dependence
Palantir secured the seven-year contract in 2023 to develop software linking data across NHS organisations, with the platform intended to reduce waiting lists and improve hospital efficiency.
More than half of NHS trusts in England now use the technology, which NHS figures suggest has helped deliver 110,000 additional operations.
Health minister James Frith said ending the agreement in 2027 would risk disrupting services, and the government plans to begin procurement for a replacement next year.
However, Dame Chi Onwurah, chair of Parliament’s Science and Technology Committee, said the decision demonstrated the dangers of relying on a single supplier.
“The suggestion that exercising the break clause now would be too impractical only reinforces our concerns about vendor lock-in,” she said. “The government should not wait two years – it must start reducing this dependency now.”
The government has said it will encourage British technology companies to compete for the replacement contract, although it will also invite international suppliers to participate.
Rupal Karia, senior vice-president at German software firm Celonis, welcomed the decision to keep the procurement process open to trusted European partners.
“Keeping flagship British tenders, like the £330m NHS data contract, open to trusted European partners naturally complements Britain’s push for fair access to ‘Made in Europe’ procurement,” he said.
He argued that digital sovereignty should focus on preventing dependence on individual suppliers rather than excluding overseas companies.
“True digital sovereignty isn’t about isolationism – it is built through trusted partnerships, open platforms that prevent single-vendor lock-in, and ensuring public institutions like the NHS always retain full control of their own data.”
Palantir faces political backlash
The decision to retain Palantir until 2029 has also drawn criticism over the company’s work with the Israeli military and US immigration authorities.
Amnesty International UK welcomed the government’s commitment to ending the contract but urged NHS organisations not to expand their use of Palantir’s technology in the meantime.
“This is a victory for healthcare workers, patients and campaigners who refused to give up,” said Tom Guha, the organisation’s crisis campaigner.
“This is welcome progress, but the job is not finished. The next two years must be about extracting Palantir from our NHS, not allowing it to become more deeply embedded.”
Palantir has defended its work with the NHS, arguing that its platform is exceeding performance targets and helping hospitals deliver more operations, speed up discharges and reduce delays in cancer diagnosis.
Tom Watson, senior vice-president at Palantir UK, said the company was “proud of our work to date”.